🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This is a brilliant collab using NeuroSense Therapeutics’s PARADIGM data and Biogen’s NfL data to advance NfL as an #ALS biomarker.

$NRSN Breakfast Club - Proud of the team and the great achievements. Anticipating the near future milestones...

$nrsn Announces Second Quarter 2023 Financial Results and Provides Business Update Main points: + Topline results expected in Q-4 2023 + Cash runway beyond topline clinical study readouts, into Q-2 2024 finance.yahoo.com/news/neurosens…

In the realm of medical advancements, there's a pressing call for progress in the treatment of ALS. With its impact on individuals and their families, finding an effective therapy isn't just a medical goal – it's a matter of compassion and hope.

🧠💡 Exploring the Mind-Body Connection: Elon Musk's mission to merge tech and neuroscience is igniting hope for Locked-in Patients. By pushing boundaries, we're on the brink of innovative breakthroughs that could transform treatment and slow down the degeneration itself.

linkedin.com/posts/alonbn_a…

finance.yahoo.com/news/neurosens…

Our Investor webinar will focus on NeuroSense’s Phase 2b ALS clinical trial design, endpoints analysis and progress, Alzheimer Disease Phase 2 study design, endpoints and progress, as well as upcoming catalysts. Register in advance for this webinar: lnkd.in/eZYxSNW4

In the next few days I'll be discussing $BCLI Adcomm and why the path of $NRSN is not only distinct but also exceptionally unique. 🧠 Mark your calendars for December when we unveil the Paradigm results. Stay tuned!

$nrsn "These results further bolster our confidence that PrimeC may offer a much-needed therapy for this debilitating disease which is ALS. We are proud that PrimeC is recognized as a leading ALS drug candidate by the top medical institutions in the world" Alon Ben-Noon

$nrsn "the results exceeded our expectations, as PrimeC increased the survival rate to the level of the healthy control and that got us very excited." Dr. Justin Ichida

Please help us reach as many as possible - share this message with your loved ones. Together, we can make a difference. 🩵 #ALS

$nrsn Breaking News! We are pleased to share that the pre-defined Per Protocol analysis of the top-line Phase 2b PARADIGM trial results revealed a statistically significant 37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential

37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential to provide a meaningful clinical benefit to people living with ALS.

In newly announced data, PrimeC (NeuroSense Therapeutics), a novel extended-release oral formulation composed of ciprofloxacin and celecoxib, slowed disease progression and improved survival in patients with #ALS at 12 months. More from our coverage: neurologylive.com/view/12-month-…

PrimeC Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS ❤️❤️ alsnewstoday.com/news/early-pri…

As previously reported, NeuroSense looks forward to reporting biomarker readouts for target engagement this month! 🙂

ICYMI. I wanted to share the press release from NeuroSense Therapeutics so that you can see for yourselves the data and make your own assessment of it. prnewswire.com/news-releases/…

$NRSN People are approaching us, asking for news. News coming your way! 🚀 We’ll be sharing our latest achievements, upcoming milestones, and future plans very soon. Stay tuned for updates!